<code id='3534D033EF'></code><style id='3534D033EF'></style>
      • <acronym id='3534D033EF'></acronym>
      <center id='3534D033EF'><center id='3534D033EF'><tfoot id='3534D033EF'></tfoot></center><abbr id='3534D033EF'><dir id='3534D033EF'><tfoot id='3534D033EF'></tfoot><noframes id='3534D033EF'>
      • <optgroup id='3534D033EF'><strike id='3534D033EF'><sup id='3534D033EF'></sup></strike><code id='3534D033EF'></code></optgroup>
        5. <b id='3534D033EF'><label id='3534D033EF'><select id='3534D033EF'><dt id='3534D033EF'><span id='3534D033EF'></span></dt></select></label></b><u id='3534D033EF'></u>
          <i id='3534D033EF'><strike id='3534D033EF'><tt id='3534D033EF'><pre id='3534D033EF'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-09-29 02:14:48 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：27
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          The stability of $0 premiums in Medicare Advantage
                                
                            
          Next article：  
                                      
                                          Duchenne breakthrough therapy leaves behind pioneering families
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles